Precision BioSciences (NASDAQ: DTIL) CEO receives 573,888 restricted stock units

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Amoroso Michael reported acquisition or exercise transactions in this Form 4 filing.

PRECISION BIOSCIENCES INC President and CEO Michael Amoroso reported a compensation-related equity grant. He received 573,888 Restricted Stock Units, each representing a contingent right to receive one share of the company’s common stock. The award vests in three substantially equal annual installments beginning on February 18, 2027, conditioned on his continued service with the company. Following this grant, his reported holding of these RSUs is 573,888 units.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Amoroso Michael

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	573,888	$0.00	--

Holdings After Transaction: Restricted Stock Units — 573,888 shares (Direct, null)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. Award vests in three substantially equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Key Figures

RSUs granted: 573,888 units Transaction price per RSU: $0.00 per unit Underlying common shares: 573,888 shares +3 more

6 metrics

RSUs granted 573,888 units Grant of Restricted Stock Units to CEO Michael Amoroso

Transaction price per RSU $0.00 per unit Grant/award acquisition, not open-market purchase

Underlying common shares 573,888 shares Each RSU represents one share of common stock

RSUs after transaction 573,888 units Total reported RSU holdings following this grant

Vesting start date February 18, 2027 First of three substantially equal annual installments

Vesting structure Three annual installments Vests in three substantially equal annual tranches

Key Terms

Restricted Stock Units, contingent right, vesting, Common Stock

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"represents a contingent right to receive one share of the Issuer's Common Stock"

vesting financial

"Award vests in three substantially equal annual installments beginning on February 18, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"receive one share of the Issuer's Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/03/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Amoroso Michael

(Last)

(First)

(Middle)

C/O PRECISION BIOSCIENCES, INC.

302 E. PETTIGREW STREET, SUITE A-100

(Street)

DURHAM

NORTH CAROLINA

27701

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	06/01/2026		A		573,888		⁽²⁾	⁽²⁾	Common Stock	573,888	$0	573,888	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

2. Award vests in three substantially equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Remarks:

	/s/ John Alexander Kelly, Attorney-in-fact for Michael Amoroso	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did DTIL President and CEO Michael Amoroso report?

Michael Amoroso reported receiving 573,888 Restricted Stock Units as an equity award. Each RSU represents a contingent right to one share of Precision BioSciences common stock, reflecting compensation rather than an open-market stock purchase or sale.

How many Restricted Stock Units did the DTIL CEO receive in this Form 4?

The CEO received 573,888 Restricted Stock Units in this filing. These units convert into an equal number of common shares if vesting conditions are met, aligning part of his compensation with future company performance and continued service.

What are the vesting terms for Michael Amoroso’s DTIL Restricted Stock Units?

The RSU award vests in three substantially equal annual installments starting on February 18, 2027. Vesting is subject to Amoroso’s continued service with Precision BioSciences through each applicable vesting date, tying this grant to his ongoing employment.

Does this DTIL Form 4 reflect an open-market stock purchase or sale?

No, the filing shows a grant of Restricted Stock Units as compensation, coded as a grant or award acquisition. There are no open-market purchases or sales reported, and the transaction price per unit is listed as zero dollars per share.

How many DTIL RSUs does the CEO hold after this reported grant?

After the reported grant, the CEO’s total reported holding of these Restricted Stock Units is 573,888 units. These RSUs are derivative securities that may settle into common stock if the vesting schedule and continued service conditions are satisfied over time.